Supporting the Primary Outcomes of the Mirai Trial for the Adjunctive Digital Therapeutic Rejoyn (CT-152): Post Hoc Analyses of Meaningful Change in the Montgomery-Åsberg Depression Rating Scale and Efficacy on Clinician- and Patient-Rated Scales for Depressive Symptoms (Preprint)
Authors:
- Stacie HudgensSHStacie Hudgens
- Intan PurnajoIPIntan Purnajo
- Libby FlodenLFLibby Floden
- Steve HwangSHSteve Hwang
- Jessica AshJAJessica Ash
- Brian RothmanBRBrian Rothman
- Austin SpeierASAustin Speier
- Ainslie ForgesAFAinslie Forges
Preprint
- 30 September 2025
- preprint
- Published by JMIR Publications Inc. in JMIR Preprints
Abstract
BACKGROUND Rejoyn® (CT-152) is a prescription digital therapeutic (DTx) adjunct to antidepressive medication authorized for patients with major depressive disorder (MDD). To better understand the patient benefit of DTx and other treatment modalities, current regulatory standards support the use of modern psychometric methods to interpret the clinical meaningfulness of treatment effects for patients. In the primary analysis of Rejoyn from the pivotal, Phase 3 Mirai Trial (NCT04770285), Rejoyn showed a broad risk-to-benefit profile as demonstrated on multiple clinician- and patient-rated scales, including the primary efficacy outcome measure, the Montgomery-Åsberg Depression Rating Scale (MADRS). These findings supported FDA authorization of Rejoyn as a prescription DTx. However, the clinical relevance of these changes in the MADRS score are not immediately interpretable in clinical practice. Here, we present the results from several post hoc analyses of the Mirai trial data to support the interpretation of clinically meaningful treatment differences on clinician- and patient-reported change in depressive symptoms. OBJECTIVE This study had 2 main objectives: (1) establish threshold parameters that allow for clinically meaningful interpretation of the Mirai results in clinical practice, based on the clinical trial endpoints of change from baseline in depressive symptoms and (2) apply this threshold in a responder and sensitivity analysis in the intent-to-treat (ITT) population (which is more frequently reported in pharmacological trials) to further support the interpretation of change in unblinded analysis of the Mirai results. METHODS For the Mirai meaningful within-patient change (MWPC) analysis, anchor-based methods were used to define an MWPC threshold by exploring the associations between the MADRS, and the clinician-rated Clinical Global Impression-Severity scale (CGI-S) and the patient-reported Patient Health Questionnaire 9-Item scale (PHQ-9). Additional post hoc efficacy analyses (including that of responders) are reported for the ITT population. RESULTS Using the MWPC thresholds of 8 and 10 points (derived with the CGI-S and PHQ-9 as anchor measures, respectively), the distribution of MADRS responders favored the Rejoyn group over the sham group, and the Rejoyn group had 24%-47% higher odds of meaningful improvement on the MADRS. Post hoc ITT analyses also favored the Rejoyn group over the sham group for response rates and PHQ-9 and CGI-S score change from baseline. CONCLUSIONS Results are consistent with the primary findings of the Mirai trial, supporting the efficacy of Rejoyn as an adjunctive treatment to antidepressive medication monotherapy for adults with MDD. The MWPC analyses offered a measure of meaningful change on the MADRS, providing a framework of clinical meaningfulness for the Mirai trial findings. CLINICALTRIAL NCT04770285Keywords
This publication has 24 references indexed in Scilit:
- A digital therapeutic (CT-152) as adjunct to antidepressant medication: A phase 3 randomized controlled trial (the Mirai study)Journal of Affective Disorders, 2025
- An Interview With the Food and Drug Administration About Draft Patient-Focused Drug Development Guidance 3: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome AssessmentsValue in Health, 2023
- The growing field of digital psychiatry: current evidence and the future of apps, social media, chatbots, and virtual realityWorld Psychiatry, 2021
- Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral AntidepressantJournal of Affective Disorders, 2021
- Apps for Depression: Are They Ready to Work?Current Psychiatry Reports, 2020
- Standalone smartphone apps for mental health—a systematic review and meta-analysisnpj Digital Medicine, 2019
- Geographic Variation in the Supply of Selected Behavioral Health ProvidersAmerican Journal of Preventive Medicine, 2018
- Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scoresQuality of Life Research, 2017
- What does the MADRS mean? Equipercentile linking with the CGI using a company database of mirtazapine studiesJournal of Affective Disorders, 2017
- The structure of the Montgomery–Åsberg depression rating scale over the course of treatment for depressionInternational Journal of Methods in Psychiatric Research, 2013